Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZL-1218 with or without pembrolizumab in advanced solid tumors
NCT05859464Phase 1Terminated
- Sponsor
- Zai Lab
- Start
- Jul 2023
- Primary completion
- Aug 2025
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label trial of ZL-1218 in malignant solid tumor (4 arms), sponsored by Zai Lab. Primary endpoints: Dose Limiting Toxicities at 24 months, Treatment Emergent Adverse Events at 24 months and 4 more. Started Jul 2023; status: terminated.
02
Drugs
ZL-1218
03
Conditions
malignant solid tumor
Beyond the preview
Go deeper on NCT05859464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05859464.